through the use of differentiated mechanisms of actions including antibody-drug conjugates, antibodies and proteins. We focus on advancing therapies that leverage our core strengths in ...
Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody ...
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to GSK5764227 (GSK’227) for the treatment of adult patients with relapsed or refractory (R/R) osteosarcoma who have ...
Celltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its ...
Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...
Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...
Ltd. has exercised its exclusive option to acquire global development, manufacturing, and commercialization rights for an antibody-drug conjugate (ADC) from DualityBio, a collaborator of Nona ...
GSK5764227 (HS-20093) is a novel antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload.